Cell Therapy News

What if the next paradigm shift in cancer treatment isn’t something new? What if it is something that has been on super-low burn for an entire generation?

A novel chimeric antigen receptor T-cell therapy showed clinically relevant antitumor activity in nine of 11 younger patients with relapsed or refractory acute myeloid leukemia, according to early data from a phase 1/phase 2 study.

A novel chimeric antigen receptor T-cell therapy induced responses in the first 12 evaluable patients with relapsed or refractory multiple myeloma treated in a phase 1 dose-escalation trial.

Nearly 40% of patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma responded to therapy with afamitresgene autoleucel, according to results of a phase 2 study.

Chimeric antigen receptor T cells have emerged “as a promising therapeutic avenue” for the treatment of glioblastoma, though various factors still limit its efficacy, according to a review published in Neurology.

The FDA granted priority review to ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory multiple myeloma, according to the agent’s manufacturer.

The FDA granted fast track designation to AIC100, a chimeric antigen receptor T-cell therapy, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer, according to the agent’s manufacturer.

The FDA cleared an investigational new drug application for GDX012, a gamma-delta T-cell therapy, for patients with previously treated hematologic malignancies.

Patients with cancer who received genetically modified immune effector cells did not demonstrate increased risk for developing subsequent malignancies, according to results of a retrospective study.

A natural killer T-cell therapy expressing a chimeric antigen receptor demonstrated antitumor activity among children with late-stage neuroblastoma, according to updated results of a phase 1 dose-escalation trial.